Systemic fungal infections
On this page
01
Overview
Systemic (deep or invasive) fungal infections occur when fungi that usually live harmlessly on body surfaces or in the environment invade tissues and spread to organs — lung, blood, meninges, bone, eye and skin. They divide broadly into opportunistic mycoses (candidiasis, aspergillosis, cryptococcosis) that exploit immunosuppression, and the endemic dimorphic mycoses (histoplasmosis, coccidioidomycosis, blastomycosis) that infect anyone from an environmental source. With HIV a leading driver in sub-Saharan Africa, cryptococcosis and histoplasmosis are major causes of death in advanced AIDS — yet both are diagnosable at the bedside and treatable with antifungals that every clinician should know.
A chronic “TB-like” illness that fails TB treatment — especially with meningitis, skin lesions or adrenal failure in an HIV-positive patient — should trigger fungal antigen testing before giving more antibiotics.
02
Learning objectives
- List the major systemic fungi and their routes of acquisition.
- Identify the patients at highest risk: HIV, neutropenia, steroids, transplant, diabetes.
- Recognise the clinical syndromes: oral and oesophageal candidiasis, invasive candidiasis, aspergillosis, cryptococcal meningitis, histoplasmosis.
- Select diagnostic tests: microscopy, culture, cryptococcal antigen, galactomannan, β-D-glucan, imaging.
- Prescribe the main antifungals with correct dosing and safety monitoring.
03
Important systemic fungi
Scroll the table sideways on a smaller screen.
| Fungus | Type / acquisition | Classic clinical picture |
|---|---|---|
| Candida albicans and other species | Yeast; normal flora of mouth, gut and vagina | Oral and oesophageal thrush; invasive candidaemia in lines, ICU patients and neutropenia |
| Aspergillus fumigatus | Mould; inhaled spores from decaying matter | Invasive pulmonary aspergillosis in neutropenia; allergic bronchopulmonary aspergillosis in asthma |
| Cryptococcus neoformans | Encapsulated yeast; pigeon/bat droppings, soil | Meningitis in advanced HIV; pulmonary and disseminated disease |
| Histoplasma capsulatum | Dimorphic; bird/bat-droppings-enriched soil | Pneumonia, disseminated reticuloendothelial disease with fever, weight loss, hepatosplenomegaly |
| Coccidioides spp. | Dimorphic; desert dust (Americas) | Pneumonia with erythema nodosum; meningitis in dissemination |
| Mucorales (mucormycosis) | Mould; uncontrolled diabetes, ketoacidosis, iron overload | Rhinocerebral disease with black palatal eschar — a surgical emergency |
04
Risk factors and pathogenesis
Immunity to fungi rests on neutrophils and T-cell–mediated immunity. Defects in these defences define the at-risk population: advanced HIV (CD4 under 100–200 cells/µL), chemotherapy-induced neutropenia, high-dose or prolonged corticosteroids, transplant immunosuppression, poorly controlled diabetes, malignancy, malnutrition and critical illness with central lines and broad-spectrum antibiotics. Inhaled conidia that a healthy lung clears can germinate and invade blood vessels when defences fail — hence haemoptysis and infarcted cavitary lesions in aspergillosis, and vascular invasion with stroke in mucormycosis.
05
Clinical syndromes
Candidiasis
Oral thrush: removable white plaques on an erythematous base, burning and taste disturbance; a marker of immunosuppression — in an adult, always ask why (HIV, diabetes, steroids, antibiotics, chemotherapy). Oesophageal candidiasis: odynophagia and retrosternal pain with oral thrush — in AIDS it is an AIDS-defining illness. Invasive candidiasis: persistent fever despite antibiotics in a line or ICU patient, with chorioretinal or skin lesions; blood cultures are often negative.
Aspergillosis
Invasive pulmonary aspergillosis in neutropenia: fever, cough, pleuritic pain, haemoptysis; a halo sign (ground-glass around a nodule) on CT is early, and an air-crescent sign later. Allergic bronchopulmonary aspergillosis (ABPA) in asthma: wheeze, fleeting pulmonary infiltrates, brown mucus plugs, very high IgE.
Cryptococcosis
Subacute meningitis over weeks: headache, fever, neck stiffness, vomiting, confusion and cranial-nerve palsies, in a patient with advanced HIV. Raised intracranial pressure is common and dangerous. Disseminated skin lesions (umbilicated papules mimicking molluscum) point to the diagnosis.
Histoplasmosis
Acute pulmonary: fever, cough, chest pain after cave or chicken-house exposure. Disseminated: weeks of fever, weight loss, hepatosplenomegaly, anaemia, oral ulcers and adrenal failure in advanced AIDS — a classic TB mimic.
06
Diagnosis
Scroll the table sideways on a smaller screen.
| Test | Use | Caution |
|---|---|---|
| India ink stain of CSF | Visualise encapsulated cryptococci | Insensitive (about 50%); positive in heavy loads |
| Cryptococcal antigen (CrAg) — serum and CSF lateral flow | Rapid, sensitive bedside test for cryptococcosis | Screen HIV patients with CD4 under 100 even without symptoms (CRAG screening) |
| Fungal culture (blood, sputum, CSF, tissue) | Species identification and susceptibility | Slow (days–weeks); alert laboratory — mould cultures are an aerosol hazard |
| Galactomannan antigen (serum/BAL) | Early marker of invasive aspergillosis | False positives with piperacillin-tazobactam and gut translocation |
| β-D-glucan | Screen for many invasive fungal infections | Does not detect cryptococcus or mucormycosis; false positives with dialysis, some antibiotics |
| Histoplasma antigen (urine/serum) | Rapid diagnosis of disseminated histoplasmosis | Cross-reacts with other dimorphic fungi |
| Histopathology of tissue | See yeast, pseudohyphae, hyphae or spherules | Guides urgent therapy (e.g., mucormycosis needs surgery plus amphotericin) |
07
Antifungal pharmacology
Scroll the table sideways on a smaller screen.
| Drug | Dose | Mechanism / indications | Adverse effects, contraindications, interactions |
|---|---|---|---|
| Fluconazole | Oral/IV candidiasis: 100–200 mg daily × 7–14 days; oesophageal: 200–400 mg daily × 14–21 days; cryptococcal consolidation: 400 mg daily (after induction) | Azole; blocks ergosterol synthesis. Thrush, oesophageal candidiasis, cryptococcosis consolidation, some histoplasmosis | Hepatotoxicity, QT prolongation; CYP inhibitor — raises levels of warfarin, phenytoin, some ARVs; resistance common in recurrent Candida |
| Amphotericin B (liposomal) | 3–4 mg/kg IV daily; conventional deoxycholate 0.7–1 mg/kg IV daily where liposomal unavailable | Binds ergosterol → membrane pores. Severe/disseminated disease: cryptococcal and histoplasma meningitis induction, invasive aspergillosis, mucormycosis | Nephrotoxicity (pre-hydrate; monitor creatinine, K+, Mg2+), infusion reactions (“shake and bake”: fever, rigors — give paracetamol/pethidine and slow the infusion), anaemia. Liposomal is far better tolerated |
| Flucytosine (5-FC) | 25 mg/kg QDS orally (e.g., 100 mg/kg/day divided) — only with level monitoring where available | Pyrimidine analogue; used with amphotericin in cryptococcal meningitis induction | Bone-marrow suppression (monitor FBC), hepatotoxicity; resistance emerges if used alone — always combine |
| Voriconazole | Loading 6 mg/kg IV BD × 2 doses, then 4 mg/kg BD IV or 200 mg BD orally | Azole of choice for invasive aspergillosis; good CNS penetration | Visual disturbance (reversible), hepatotoxicity, phototoxicity (counsel sun protection), therapeutic drug monitoring advised; strong CYP interactions; avoid with rifampicin |
| Itraconazole | 200 mg BD (capsules with food or acidic drink for absorption) | Azole for histoplasmosis, sporotrichosis, some aspergillosis | Absorption is erratic (check levels where available); negative inotropy — avoid in heart failure; CYP interactions |
| Caspofungin (echinocandin) | Loading 70 mg IV, then 50 mg IV daily | Inhibits β-glucan synthesis; candidaemia and salvage aspergillosis | Mild — infusion reactions, liver enzyme rise; poor CSF penetration |
| Terbinafine | 250 mg daily PO (weeks–months) | Allylamine for dermatophyte and some invasive disease | Taste disturbance, hepatotoxicity, rare marrow suppression — check LFTs on long courses |
HIV-associated cryptococcal meningitis (standard approach)
Confirmed disease: induction with liposomal amphotericin B 3–4 mg/kg IV daily plus flucytosine 25 mg/kg QDS for 7 days, then consolidation fluconazole 400 mg daily for 8 weeks, then maintenance fluconazole 200 mg daily (continue until immune recovery on ART). Where amphotericin or flucytosine are unavailable, use fluconazole 1,200 mg daily — inferior but better than nothing. Manage raised intracranial pressure aggressively with repeated lumbar punctures/CSF drainage; start ART 2–6 weeks after antifungal therapy begins.
08
Monitoring and safety
- Azoles — liver tests at baseline and during therapy; review every drug on the chart for CYP interactions (rifampicin lowers azole levels; azoles raise warfarin, phenytoin and statin levels).
- Amphotericin B — daily creatinine, K+, Mg2+, FBC; hold or reduce when creatinine rises significantly.
- Flucytosine — FBC and renal function; dose-adjust in renal impairment.
- Voriconazole — trough levels where available, visual symptoms, LFTs, skin sun-protection advice.
- Pregnancy — avoid azoles where possible in the first trimester; amphotericin B is the drug of choice for serious fungal disease in pregnancy.
09
Clinical scenario
A 34-year-old man with known HIV, not on antiretrovirals, presents after 3 weeks of progressive headache, fever and confusion. CD4 count is 28 cells/µL. Neck stiffness is present, and he has a few umbilicated papules on his face. Serum CrAg is positive. Lumbar puncture shows elevated opening pressure. Diagnosis: AIDS-associated cryptococcal meningitis. Manage: admit; begin liposomal amphotericin B 3–4 mg/kg IV daily plus flucytosine 25 mg/kg QDS for 7 days with pre-hydration and electrolyte monitoring; relieve the raised pressure with therapeutic lumbar punctures (remove 10–20 mL CSF, repeat daily while pressure is high); start fluconazole consolidation, then ART after 2–6 weeks. Oral thrush is not a prerequisite — this man needs antifungals, not another antibiotic course. If only fluconazole is available, use 1,200 mg daily and refer urgently for amphotericin.
10
Key points
11
References
- SlideShare: Systemic mycoses (Library reference.)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Library reference.)
- Davidson’s Principles and Practice of Medicine (Library reference.)
- WHO consolidated guidelines on HIV-associated cryptococcal disease (Library reference.)
12
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.